1. Streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis from retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report.
- Author
-
Fujimoto S, Eriguchi Y, Nakamura R, Kamikawa S, Yonekawa A, Miyake N, Ono N, and Niiro H
- Subjects
- Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Still's Disease, Adult-Onset diagnosis, Still's Disease, Adult-Onset complications, Still's Disease, Adult-Onset drug therapy, Receptors, Interleukin-6 antagonists & inhibitors, Treatment Outcome, Retroperitoneal Space, Shock, Septic etiology, Shock, Septic drug therapy, Shock, Septic diagnosis, Shock, Septic microbiology, Streptococcal Infections diagnosis, Streptococcal Infections drug therapy, Streptococcal Infections complications, Streptococcal Infections microbiology, Panniculitis diagnosis, Panniculitis etiology, Panniculitis microbiology, Panniculitis drug therapy, Streptococcus immunology
- Abstract
A 53-year-old man with adult-onset Still's disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation., (© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF